Gout occurs in individuals who have high serum uric acid levels, in response to precipitation of monosodium urate monohydrate crystals in various tissues, followed by an inflammatory response.
Hypouricemic Action of Selected Flavonoids in Mice: Structure-Activity Relationships
Animals Male ICR mice (25-28 g ) were provided by Shanghai Experimental Animal Center of Chinese Academy of Sciences. They were allowed at least 1 week to adapt to their environment before used for experiments. Animals were housed individually and allowed to access to standard laboratory diet and tap water freely. The animal rooms were controlled at room temperature (25Ϯ2°C), humidity (55Ϯ5%), and light (12 h light-dark cycle).
Animal Model of Hyperuricemia A hyperuricemic animal model was induced by potassium oxonate, a urate oxidase inhibitor. 22, 23) Briefly, mice were intraperitoneally injected with potassium oxonate (250 mg/kg body weight) 1 h before the last drug administration. Potassium oxonate was suspended in 0.5% sodium carboxymethylcellulose (CMCNa) freshly prepared before use. Control animals were manipulated in parallel with 0.5% CMC-Na injection. After 2 h from injection of potassium oxonate, blood samples were collected from the tail vein of the mice and then were centrifuged at 3500ϫg for 5 min. Supernatant serum was collected and stored at Ϫ20°C until assayed.
Drug Administration In the preliminary experiments, mice were firstly randomized into various groups (nϭ10): normal control, model control, positive control and drug groups. Quercetin, morin, myricetin, kaempferol, icariin, apigenin, luteolin, baicalin, silibinin, naringenin, formonoetin, genistein, puerarin, daidzin and naringin dihydrochalcone were dissolved or suspended in 0.5% CMC-Na. Animals were fasted for 2 h before drug administration. All the flavonoids at 50 and 100 mg/kg body weight were orally given to the mice once a day for three consecutive days. Allopurinol as a positive control was orally given in parallel at 10 mg/kg body weight. At the same time, the normal control and model control groups were orally administrated with 0.5% CMC-Na for 3 d.
Liver Sample Preparation Livers were surgically excised from the mice that had been killed by decapitation. Excised liver was rinsed in a saline buffer, cut into two pieces and frozen in liquid nitrogen, and stored at Ϫ80°C until homogenized. One piece was homogenized in an ice-cold 50 mM potassium phosphate buffer, pH 7.8. The homogenate was centrifuged at 1500 g at 4°C for 10 min and the pellet was discarded. The supernatant fraction was used to measure uric acid concentration. The other piece was homogenized in an ice-cold 50 mM potassium phosphate buffer, pH 7.8 containing 1 mM ethylenediaminetetraacetic acid disodium salt (EDTA-Na) and 1 mM phenylmethanesulfonyl fluoride (PMSF). The homogenate was centrifuged at 1500 g at 4°C for 10 min and the pellet was discarded. The supernatant fraction was used to detect XOD activity.
Uric Acid Assay Serum and liver uric acid concentrations were determined by the phosphotungstic acid method according to Carroll et al. 24) Liver XOD Activity Assay XOD activity in mouse liver was measured by the modified method described previously. 25, 26) Briefly, XOD activity was determined in a 50 mM potassium phosphate buffer, pH 8.0 containing 1 mM EDTANa with the presence of 100 mM xanthine as the substrate. The mixture was incubated at 37°C for 30 min. The reaction was stopped by the addition of 0.5 ml 0.58 M HCl. The production of uric acid was measured by determining the UV absorbance at 290 nm. Protein concentration was determined by the method of Lowry et al. 27) using BSA as the standard. One unit of enzyme activity was defined as the amount of enzyme required to convert 1 nmol of xanthine to uric acid per minute per mg protein at 37°C.
Statistical Analysis Each experiment was performed in. Results were presented as the mean valuesϮS.E.M. To determine statistical significance, experimental data was evaluated using the unpaired Student's t-test by the Statistical Analysis System (GraphPad Prism 4, GraphPad Software, Inc., San Diego, CA, U.S.A.). For all the analyses, a value of p<0.05 was considered statistically significant.
RESULTS

Hypouricemic Action in Hyperuricemic Mice
Nomenclature of the subclasses of flavonoids according to their substituents and the effects of 15 flavonoids on serum uric acid levels in hyperuricemic mice were shown in Table 1 . Compared with the uric acid value (3.30 mg/dl) of the normal mice, the serum uric acid levels (4.38 mg/dl) of the model mice were significantly increased by the inducement of potassium oxonate (p<0.001). Allopurinol, as a positive control, significantly reduced the levels of serum uric acid to 2.70 mg/dl lower than the normal levels in hyperuricemic mice at 10 mg/kg (p<0.05). Six of 15 flavonoids, quercetin, morin, myricetin, kaempferol, apigenin and puerarin could significantly lower the uric acid levels of hyperuricemic mice to normal levels both at 50 and 100 mg/kg. Luteolin, formonoetin and naringenin showed their significant effects just at the high dose (100 mg/kg). But the hypouricemic effects of all compounds were milder than that of allopurinol. Genistein, baicalin, icariin, daidzin, naringin dihydrochalcone and silibinin had no effects on the serum uric acid levels in hyperuricemic mice.
The effects of six active flavonoids (quercetin, morin, myricetin, kaempferol, apigenin and puerarin) on liver uric acid levels in hyperuricemic mice were also observed and the results were showed in Fig. 1 . Compared with normal group, the liver uric acid levels in hyperuricemic mice were significantly higher. Allopurinol exhibited a remarkable reduction in liver uric acid levels in hyperuricemic animals and the levels were lower than that of normal animals. Compared with normal control, quercetin, puerarin, myricetin, morin and kaempferol were also found to be effective in reducing liver uric acid levels, and the uric acid levels at high dose group of each compound were reduced to normal levels. However, apigenin showed no significant effects on liver uric acid levels in hyperuricemic animals even at higher dose.
Hypouricemic Action in Normal Mice Normal mice were orally treated with quercetin, morin, myricetin, kaempferol, apigenin and puerarin for 3 d. The actions of these compounds on serum and liver uric acid concentrations in normal mice were showed in Table 2 . Allopurinol significantly reduced the uric acid levels both in serum (p<0.001) and liver (p<0.05) of normal mice. In quercetin, kaempferol, apigenin and puerarin groups, the serum uric acid levels were reduced to different extents. Kaempferol significantly reduced the serum uric acid levels of normal animals both at dosages used, and quercetin and puerarin showed significant hypouricemic effects only at higher dose. Myricetin, apigenin and morin at doses tested were ineffective on the The hyperuricemic mice were induced by potassium oxonate injection 1 h before the last drug administration. Flavonoids and allopurinol were orally administrated once daily for 3 d. The hyperuricemic and normal controls were orally administered with 0.5% CMC-Na for 3 d. The serum uric acid levels of mice were measured. Data represented mean valueϮS.E.M. of serum uric acid level (mg/dl) in 10 mice. The serum uric acid levels of hyperuricemic mice were significantly higher than that of normal mice and they were 4.38 mg/dl and 3.30 mg/dl, respectively. Allopurinol significantly reduced the level of serum uric acid in hyperuricemic mice at 10 mg/kg to 2.70 mg/dl, which was lower than the normal level (p<0.05). For statistical significance, * p<0.05, * * p<0.01 and * * * p<0.001 when the drug treated groups were compared with the hyperuricemic mice (Model control); # p<0.05, ## p<0.01 and ### p<0.001 when the drug treated groups were compared with the normal mice (Normal control). Gluϭglucose; GlcAϭglucuronide; Rhaϭrhamnose; R 1 ϭ-CH 2 -CHϭCMe 2 ; R 2 and R 3 were shown in the structure of silibinin. serum uric acid levels of normal mice. For the uric acid levels in liver of normal mice, all above flavoniods were found ineffective at doses tested.
Effect on Liver XOD Activity in Mice After 3-d treatments, the effects of flavonoids on the liver XOD activity in mice were investigated and the results were showed in Table  3 . Allopurinol significantly suppressed the liver XOD activity (71.92%) in mice. Quercetin showed a weak inhibition on liver XOD activity and just had significant effect at the higher dose (27.19%) . Morin, myricetin, kaempferol and puerarin exhibited significant inhibition on the liver XOD activity both at lower and higher dose used. But the inhibitions on liver XOD activity of flavonoids observed at higher dose (55. 26, 59 .65, 43.86, 39.47%) were much weaker than that of allopurinol. However, apigenin failed to inhibit liver XOD activity.
DISCUSSION
Hyperuricemia is the most important risk factor for the development of gout 28) and occurs as a result of increased uric acid production, impair renal uric acid excretion, or a combination of these mechanisms. Control of hyperuricemia is most often achieved by reducing uric acid production with an inhibitor of XOD, the enzyme catalyzing the two terminal reactions in uric acid synthesis (the oxidation of hypoxanthine to xanthine and of xanthine to uric acid). Accordingly, the use of the XOD inhibitor that blocks the synthesis of uric acid in the body should be one of the therapeutic approaches for the treatment of hyperuricemia. 29) In the present study, six of 15 flavonoids, quercetin, morin, myricetin, kaempferol, apigenin and puerarin were confirmed to possess strong hypouricemic actions in hyperuricmic mice both at 50 and 100 mg/kg. Luteolin, formonoetin, narin-1554
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Fig. 1. Effects of Flavonoids on Liver Uric Acid Levels
The hyperuricemic mice were induced by potassium oxonate injection 1 h before the last drug administration. Allopurinol (APU) at 10 mg/kg and flavonoids at 50 and 100 mg/kg were orally administrated once a day for 3 d. The model and normal controls were orally administered with 0.5% CMC-Na for 3 d. Liver uric acid levels were measured by the method described in Materials and Methods. Data represented mean valueϮS.E.M. (nϭ10) of liver uric acid levels (mg/g wet tissue). For statistical significance, * p<0.05, * * p<0.01 and * * * p<0.001 when the drug treated groups were compared with the hyperuricemic mice (Model control); # p<0.05, ## p<0.01 and ### p<0.001 when the drug treated groups were compared with the normal mice (Normal control). Normal mice were orally administrated drugs once daily for 3 d. Data represented mean valueϮS.E.M. of serum uric acid levels (mg/dl) and liver uric acid levels (mg/g wet tissue) in 10 mice. For statistical significance, * p<0.05, * * p<0.01 and * * * p<0.001 when the drug treated groups were compared with the normal mice (normal control). genin, and daidzin exhibited the significant hypouricemic effects just at 100 mg/kg, while genistein, baicalin, naringin dihydrochalcone and silibinin had no effects. Six active flavonoids including quercetin, morin, myricetin, kaempferol, apigenin and puerarin were further studied on liver uric acid levels and liver XOD activity. Except apigenin, quercetin, puerarin, myricetin, morin and kaempferol were also found to be effective in reducing liver uric acid level in hyperuricemic mice, and the uric acid levels at higher dose groups of each compound were reduced to normal level. Quercetin, morin, myricetin, kaempferol and puerarin also exhibited significant inhibition on the liver XOD activity. It seems likely that these flavonoids reduce serum urate levels by mainly inhibiting liver XOD activity. Myricetin and genistein were found to exhibit competitive inhibition on XOD activity in vitro. 30) The hypouricemic effects and the inhibitions on XOD activity of morin, acacetin, catechin and epicatechin were observed in a hyperuricemic rat model. 20, 21) These results partly supported our study. However, in this study, apigenin showed hypouricemic effect in hyperuricemic mice, but no effects on either liver uric acid level or liver XOD activity, indicating that apigenin might be acting via other mechanisms apart from simple inhibition of the enzyme activity. On the other hand, the effects of flavonoids on enzymes were generally dependent on the concentration of flavonoids present, and the different flavonoids ingested. 10) The concentrations achieved in vivo may not reflect the concentrations tested under in vitro condition. Bioactivity will also vary with the tissue distribution of enzymes, with the species used in testing. Future studies will still be continued to elucidate the exact mechanism of the action of flavonoids in vivo.
As reported, there is a tight correlation between the considered structures and the observed pharmacological effects of flavonoids. 8, 31) Structure-activity relationships of flavonoids have been proposed for the antioxidant and the antispasmodic effects. 31) Due to the presence of different substituents on the carbon atoms of the basic skeleton, flavonoids may have different activities and potencies. 32) According to our results, flavonols (quercetin, morin, myricetin, kaempferol) are present of C-2-C-3 double bond with hydroxyl groups in position 3, 5 and 7. They were active in the hypouricemic and XOD inhibitory properties in hyperuricemic mice. Glycosylation on the position 7 might cause icariin lose the hypouricemic actions and the XOD inhibitory activity. Contrarily, the hypouricemic effects of flavones were diminished by absence of the 3-hydroxyl group (luteolin). In addition, the removal of 4Ј-hydroxyl group might cause flavone (bacalin) inactive in hypouricemic effects. Structure analysis indicated that 4Ј-hydroxyl groups were the same critical as hydroxyl groups on rings in interaction with target protein, and hypouricemic effects of quercetin, morin, myricetin, kaempferol with 4Ј-hydroxyl group were mediated by the direct inhibition on XOD activity. However, compared with luteolin, the removal of 5Ј-hydroxyl group of apigenin provided one of the most active compounds for hypouricemic action but without XOD activity. The hypouricemic mechanism of apigenin was still not clear. Saturation of the C-2, C-3 double bond of flavanoes (naringenin) and flavanonols (silibinin) weaken the hypouricemic activities of these compounds. The 3-hydroxyl group of isoflavones (formonoetin, genistein, daidzin) was replaced. Genistein has been proved with the XOD inhibitory action, but it was not confirmed in the present study. This might be due to the improper dosage. Glycosylations on 3-hydroxyl group or/and 7-hydroxyl group (icariin, baicalin, daidzin), and opening of the C ring (naringin dihydrochalcone) abolished the hypouricemic actions and inhibitory XOD activities of flavonoids. In contrast, glycosylation on position 8 increased the hypouricemic and XOD inhibitory actions of puerarin, suggesting that glycosylations on some positions might interfere with the compounds binding to the enzyme. A planar structure and the hydroxyl groups on the flavonoids may play a crucial role in the interaction with the molecular target of these compounds.
In the present study, quercetin, morin, myricetin, kaempferol, apigenin and puerarin could reduce the serum uric acid levels in normal animals to different extents, but the reductions of serum uric acid levels were much less than that of allopurinol groups in normal animals. Flavonoids have been described as health-promoting, disease-preventing dietary supplements because they are extremely safe and associated (associates) with low toxicity, making them to be excellent candidates for agents. 10) These data in normal mice also indicated that flavonoids might bring fewer side effects than allopurinol in treatment of gout and hyperuricemia.
Hyperuricemia is frequently found in these diseases in which the clinical manifestations are thought to be secondary to a state of generalized vascular endothelial dysfunction and related to the cardiovascular diseases present in conditions associated with the metabolic syndromes, such as hypertension or diabetes. 33) It is possible that the increased cardiovascular disease risk associated with the metabolic syndrome partially attributes to elevated circulating serum uric acid concentration. The mechanisms that are most often thought to link uric acid and endothelial dysfunction involve inflammation and generation of oxidative stress in the vasculature. 19) Flavonoids possess multi-bioactivity such as antihyperuricemic, anti-inflammatory and antioxidant activities. [13] [14] [15] [16] In fact positive healthy effects of flavonoids have also been reported in several diseases, such as cardiovascular diseases and cancer. 17, 18) Moreover, the hypouricemic and XOD inhibitory actions of flavonoids have been confirmed in this study. These results mentioned above suggested that the flavonoids could improve the metabolic syndromes related to hyperuricemia.
Summarily, the data in the present study indicated that flavonoids possessed hypouricemic actions in hyperuricemic mice, at least partly, due to their inhibitory effects on XOD activity. These results provided the basis for flavonoids to treat hyperuricemia and the metabolic syndrome.
